Alzheimer Society International Congress™ (ASIC 2024™)

ASIC 2024™ will be held on November 12-14, 2024 in San Francisco. ASIC 2024 is a leading forum in Alzheimer research and dementia care. The Congress will highlight the latest accomplishments in Alzheimer research and best practice in patient care.

The theme of the 2024 Congress is “The Next Frontier Against Alzheimer's”.

ASIC 2024 encourages new concepts and hypotheses on the etiology and potential prevention or treatment therapy, and best practice in Alzheimer’s and Dementia care. New ideas and alternatives to Amyloid cascade hypothesis such as Tau hypothesis, Calcium hypothesis, Inflammation hypothesis, Cholinergic and Oxidative stress hypothesis, Glucose hypometabolism, Endocrine pathway, Bacteria-derived metabolites and other new ideas with supporting data are welcome at the ASIC.

NEW FEATURES OF THE ASIC 2024:

ASIC 2024 will feature new symposia and forum on the following important topics
<> Forum on Alzheimer's Drug Development (ADDS)
<> Symposium on Amyloid Hypothesis and Alternative Hypotheses
<> Open Forum on Medicare's decision on reimbursemnt for Aducanumab and Lecanemab:
<> A Public Debate on Research Directions for Alzheimer's Disease

General guidelines for the layout of an abstract

Your abstract should fit into one page of standard letter size (US letter size, 8½ inches wide and 11 inches long), using font ARIAL size 12, with a layout margin of 1 inch left and right, and 1 inch top and bottom. Approximately 450-500 words of font Arial size 12 fit in to one letter size page. An abstract normally consists of the following headers with suggested number of words with some flexibilities.

1. Title of the abstract: Keep in Concise, Capitalize Each Word: about 20-30 words

2. Authors and Organization: about 10-20 words

3. Background: about 100 words

4. Methods: A brief description of the experimental method- about 150-170 words.

5. Results: A brief description of results, about 130-160 words

6. Conclusion: about 30-50 words

Submit your Abstract

Submit your abstract today.

The deadline of abstract submission is August 15, 2024 by 11:59 PM Pacific Standard Time..

PRESENTATION TYPES

Authors may apply for an oral presentation or a poster presentation when submitting an abstract for ASIC 2024. Decision will made by the Program Committee basedon the merit of the abstracts and the availability of speaking schedules.

ASIC 2024 POSTER PRESENTATION

• Grouped by topic.
• Accepted posters will be scheduled on November 12-14, 2024.
• An author may present multiple posters as long as they are scheduled on different dates.
• Poster format:
  • Layout: landscape
  • Maximum Dimensions:
    • Inches: 60 inches (wide) x 42 inches (high)
    • Meters: 1.52 meters (wide) x 1.07 meters (high)
    We advise printing your poster slightly smaller than the dimensions above to allow room for the poster number. No audiovisual equipment is available for poster presentations. Push pins will be provided.

ASIC 2024 ORAL PRESENTATION

• Oral presentation is 20 minutes including questions and answers.
• Accepted oral presentations will be scheduled for November 12-14, 2024.
• A person can be the presenting author for an oral presentation and a poster presentation .
• Submitted oral presentation abstracts that are not selected will be considered for a poster presentation.

TOPICS AND SUBTOPICS

GENETICS

• Molecular genetics
• Endophenotypes
• Genetic factors of Alzheimer's disease
• Genetics of cognitive aging

MOLECULAR AND CELL BIOLOGY

• APP/Abeta/Amyloid
• Apoptosis
• α-synuclein
• Calcium homeostasis
• Mitochondrial function/energetics
• Neurodegeneration and neuroprotection
• Neuroinflammation
• Oxidative stress
• Synaptic disruption

DIAGNOSIS AND PROGNOSIS

• Biomarkers (non-neuroimaging)
• Differential diagnosis
• Longitudinal change over time
• Method development and/or quality control
• Novel biomarkers
• Plasma/serum/urine biomarkers

CLINICAL (neuropsychiatry and behavioral neurology)

• Assessment/measurement of neuropsychiatric
• Behavioral neurology
• Dementia
• Mild cognitive impairment
• Neuropsychiatry

NEUROIMAGING

• Imaging and genetics
• Multi-modal comparisons
• New imaging methods
• Normal brain aging
• Optimal neuroimaging measures for early detection

NEUROPATHOLOGY

• Alpha-synuclein
• Amyloid
• Etiopathogenesis--links to brain disease
• Proteinopathies
• Tau
• Vascular

NEUROPSYCHOLOGY

• Early detection of cognitive decline with neuropsychological tests
• Multicultural issues in assessment of dementia
• Neuropsychological correlates of physiologic markers of cognitive decline/dementia
• Neuropsychological profiles of dementia: Valid biomarkers?

DEMENTIA CARE RESEARCH

• Assessment and care planning
• Behavioral interventions
• Cross-cultural studies and cultural
• Long-term care
• Therapeutic strategies and interventions

DEMENTIA CARE PRACTICE

• Innovative programs and practices
• Leadership and staff development
• Policy and systems change
• Program evaluation and care interventions

EPIDEMIOLOGY

• Innovative methods in epidemiology
• Prevalence, incidence, and outcomes of MCI and dementia
• Risk and protective factors in MCI and dementia

HEALTH ECONOMICS AND POLICY

• Cost-effectiveness of treatment
• Policy and plans
• Medical Insurarance and MediCare Reimbursement

PREVENTION (non-pharmacological)

• Cognitive interventions
• Exercise
• Lifestyle factors
• Multidomain
• Nutrition
• Others

PSYCHOSOCIAL FACTORS AND ENVIRONMENT DESIGN

• Environmental design and technology
• Living with dementia and quality of life
• Social networks

DEVELOPMENT OF NEW MODELS AND METHODS

• α-synuclein
• Amyloid/Abeta
• Tau
• Behavioral models
• Neuroinflammation
• Novel assays and technologies
• Screening studies/platforms

BIOINFORMATICS AND COMPUTATIONAL BIOLOGY

• Bio-informatics
• Computational Biology
• Big Data and Deep Learning
• Artificial Intelligence Applications for Alzheimer research

PRECLINICAL (nonhuman)

• Animal Models for Alzheimer research
• Target identification and validation studies: Amyloid
• Target identification and validation studies: Tau
• Target identification and validation studies: Inflammation and innate immunity
• Target identification and validation studies: Neuronal and synaptic protection
• Target identification and validation studies: Other

HUMAN CLINICAL TRIALS (THERAPEUTICS)

• Human trials: Cognitive enhancement
• Human trials: Other behavioral symptoms
• Human trials: Anti-amyloid
• Human trials: Anti-tau
• Human trials: Inflammation
• Human trials: NMDA and AMPA
• Human trials: Other Mechanism of Actions
• Novel outcomes measures
• Clinical trial design

INVESTMENT OPPORTUNITIES IN ALZHEIMER'S AND RELATED DISEASES

• Investment Perspectives in Alzheimer Industry
• New Therapeutic Prevention and Treatment Companies
• Non-Drug Therapy Companies
• Neurotech and Medical Device Companies
• Software and Artificial Intelligence
• Clinical Research Organizations
• Healthcare Services Providers

ASIC 2024 Confidentiality Agreement and Embargo Policy

All materials presented at The Alzheimer Society International Congress 2024 are embargoed for publication and broadcast until the officially scheduled date and time of presentation unless the Alzheimer International Society provides written notice of change of date and/or time in advance.